| Previous Close | 82.33 |
| Open | 81.85 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 81.59 - 82.43 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 2,582,102 |
| Avg. Volume | 2,421,799 |
| Market Cap | 100.25B |
| Beta | 0.74 |
| PE Ratio (TTM) | 11.37 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.47%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Moody's•8 hours ago
Green River (City of) WY, Variable Rate Demand Revenue Bonds (Rhone-Poulenc of Wyoming, L.P. Project), Series 1994, $11.4MM -- Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs (Rhone-Poulenc of WY, L.P.) Series 1994
Rating Action: Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs Series 1994. Global Credit Research- 27 Jul 2017. New York, July 27, 2017-- Moody's Investors Service has affirmed the A1/VMIG ...
- Barrons.com•yesterday
Eli Lilly: The Competition is Just Too Darn Intense!
Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ...
- Reuters•3 days ago
FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
